作为免疫肿瘤学的负责人, 澳门在线赌城娱乐的发现和肿瘤细胞治疗部门, I have a unique opportunity to apply my background as an immunologist and physician-scientist to translate science into potentially transformative medicines.

Our Immuno-肿瘤学 Discovery team spans all stages of discovery, from target identification and validation to clinical candidate selection. We are also focused on generating preclinical predictive models to identify patients with a higher likelihood of benefitting from different treatments. Beyond this, we are exploring the possibility of living medicines – 细胞疗法 – to rebuild the body’s own ability to recognise and attack tumours, 消灭癌细胞，实现治愈. 

是一名训练有素的免疫学家和内科科学家, 我的专长是治疗免疫缺陷患者. 我的研究方向是转化免疫学, 包括癌症免疫学和免疫疗法. My early work related to human viral immunity and restoring anti-viral immune responses through cellular immunotherapy. 通过我的研究, I developed a strong interest in tumour neoantigens – believed to play a dominant role in the immune system’s response to cancer – and have contributed to the discovery of a novel class of tumour antigens.

PL

I am particularly excited about the innovative work in 细胞疗法, 主要专注于T细胞疗法. A key aspect of our research is how we can engineer a better T cell – taking what nature has given us to the next level to detect and eradicate cancer more effectively while sparing healthy cells.

马克Cobbold Vice President Discovery and Head of 肿瘤学 Cell Therapy, 肿瘤学 R&D、澳门在线赌城娱乐

奖

2004: Young Immunologist of the Year, British Society for 免疫学

奖

2005: Best Presentation 奖, British Society for Bone Marrow Transplantation

奖

2012: Overall Winner, BIG Idea 奖, 伯明翰大学

电流的作用

Vice President Discovery and Head of 肿瘤学 Cell Therapy, 肿瘤学 R&D、澳门在线赌城娱乐

2015年至今

Associate Professor of Medicine at Harvard Medical School and Massachusetts General Hospital Cancer Center. 在MGH癌症免疫学中心成立了科博尔德实验室, which was the first to demonstrate immunity against cancer-specific phosphopeptide antigens is present in healthy individuals and patients with cancer; the first to discover major histocompatibility complex (MHC) class-I displayed N-Acetylglucosamine and methylarginine peptide neoantigens and demonstrated these are also targets of immunity in humans; and developed three novel antibody engineering approaches to redirect T-cells against tumours with high specificity (APEC, TEAC及ATTAC)

2011-2019

Co-founded five biotechnology companies over eight years (SeraScience, PhosImmune, Revitope肿瘤学, 砂石肿瘤和GigaMune)

2014-2015

翻译免疫学读本, 医学研究委员会免疫调节中心, 伯明翰大学(英国)

 特色的出版物

Aberrant X chromosome skewing and acquired clonal hematopoiesis in adult-onset common variable immunodeficiency.

Wong GK, Barmettler S, Heather JM, Millar D, 彭妮年代A, Huissoon A, Richter A, Cobbold米. 江森自控的洞察力. 2019年7月25日;4(14). 发布链接.

Immune dysregulation in immunodeficiency disorders: The role of T-cell receptor sequencing.

黄国强，Heather JM, Barmettler S， Cobbold米. J Autoimmun. 2017年6月,80:1-9. 发布链接.

Identification of Glyco¬peptides as Posttranslationally Modified Neoantigens in Leukemia.

malak SA, 彭妮年代A, Steadman LG, Myers PT, Loke JC, Raghavan M, Bai DL, Shabanowitz J, 亨特DF, Cobbold米. 癌症免疫系统. 2017年5月,5 (5):376 - 384. 发布链接. 

Accelerated Loss of TCR Repertoire Diversity in Common Variable Immunodeficiency.

Wong GK, Millar D, 彭妮年代, Heather JM, Mistry P, Buettner N, Bryon J, Huissoon AP & Cobbold米. J. Immunol. 2016年9月1日;197(5):1642-9. 发布链接.

 

MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia.

Cobbold米*, De La Peña H, 诺里斯一, Polefrone JM, 钱我, 英语是, 卡明斯KL, 彭妮年代, 特纳我, Cottine J, Abelin詹, malak SA, Zarling艾尔, 黄HW, 古德伊尔啊, 弗里曼SD, Shabanowitz J, 普拉特G, 克拉多克C, 威廉姆斯我, 亨特DF, 恩格尔哈德VH. 科学与医学. 2013年9月18日;5(203):203ra125. *通讯作者. 发布链接.

Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.

穆罕默德F __, Cobbold米†, Zarling艾尔, Salim M, Barrett-Wilt GA, Shabanowitz J, 亨特DF, 恩格尔哈德VH, Willcox BE. Nat Immunol. 2008年11月,9 (11):1236 - 43. †Co-first作者. 发布链接.

Veeva ID: Z4-49218
筹备日期:2022年10月